Can-Fite BioPharma Ltd.
CANF · AMEX
Market closed$3.40$0.080000 (+2.41%)After hours $3.24 · -4.71%
Key statistics
Previous close$3.32
Open$3.26
Day high$3.40
Day low$3.22
52-week high$21.00
52-week low$2.56
Market cap1.83M
Volume32.72K
Average volume1.90M
P/E ratio-0.50
Forward P/E—
EPS-6.83
Dividend yield0.00%
Market context
Why it moved
CANF edged higher in light trading, likely driven by modest technical buying and positive momentum as the stock climbed from its daily low, with no specific company news identified as a clear catalyst for the modest uptick.
What is happening
Recent company-specific developments and publisher coverage.
www.marketscreener.com · July 14, 2026Can-Fite Biopharma Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic CancerStock Titan · July 14, 2026Can-Fite's Namodenoson in Phase 3 liver cancer study; pancreatic trial plannedQuiver Quantitative · July 6, 2026Can-Fite BioPharma Announces Completion of Enrollment of First 247 Patients in Pivotal Phase 3 Piclidenoson Psoriasis Study Ahead of Interim AnalysisMoomoo · July 2, 2026H.C. Wainwright Maintains Can-Fite BioPharma(CANF.US) With Buy Rating, Raises Target Price to $8Investing.com · July 1, 2026Can Fite Biopharma stock surges 65% on pancreatic cancer dataStock Titan · June 17, 2026Can-Fite seeks new drug licenses after $20M in prior dealsGlobeNewswire · May 18, 2026Scientific Publication of Can-Fite and Vetbiolix ValidatesStock Titan · April 30, 2026One pancreatic cancer patient stays on Can-Fite drug past 16 months Mt Newswire · July 6, 2026Can-Fite BioPharma Completes Enrollment in Phase 3 Study of Potential Plaque Psoriasis Treatment Benzinga · July 6, 2026Can-Fite BioPharma Completes Enrolment Of First 247 Patients In Pivotal Phase 3 Study Evaluating Piclidenoson For Treatment Of Moderate-To-Severe Plaque Psoriasis Benzinga · July 2, 2026HC Wainwright & Co. Reiterates Buy on Can Fite Biopharma, Raises Price Target to $8 Mt Newswire · July 1, 2026Can-Fite Shares Surge After Pancreatic Cancer Study Showed Durable Survival Outcomes Benzinga · July 1, 2026Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients Benzinga · June 26, 2026Can-Fite Stock Jumps After Japan Patent Boosts Obesity Drug Case Mt Newswire · June 26, 2026Can-Fite Secures Japanese Patent for Namodenoson's Anti-Obesity Tech; Shares Up Pre-Bell Benzinga · June 26, 2026Can-Fite BioPharma Announces Japan Patent Allowance Covering Namodenoson’s Anti‑Obesity Activity